Apatinib’s primary target, VEGF pathway, had some changed genes but the pathway itself was not significantly enriched, which may be explained by the fact that VEGF pathway may be mainly active in endothelial cells, not cancer cells. This evidence concerns the gene VEGFA and cancer.